Lantheus

Member

Lantheus has spent more than 70 years advancing patient care by continuously learning, adapting, and innovating across the healthcare spectrum. As a pioneer in medical imaging, the company is now leveraging its deep expertise in radiopharmaceutical science to better understand neurological disorders such as Alzheimer’s disease. Lantheus’ product portfolio, pipeline, and research efforts are focused on key biomarkers—tau tangles and beta-amyloid plaques, hallmarks of Alzheimer’s—with the goal of developing next-generation radiodiagnostics that enable earlier detection and improve patient outcomes. For more information, please visit www.lantheus.com.